Oncology Account Manager - NYC

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

Reporting to the Regional Business Director, the Oncology Account Manager (OAM) will contribute to Kura’s overall sales objective by performing assigned Sales and Account Management related activities in the NYC territory (inclusive of the 5 boroughs). The OAM will provide physicians, pharmacists, nurses and all healthcare professionals (HCPs) with product, services and approved information that will enable the HCPs to appropriately prescribe Kura’s product(s)The OAM will compliantly and successfully implement Kura’s marketing strategies and corresponding tactics in order to achieve short-term and long-term objectives. The ideal candidate will be capable of managing the territory and administrative requirements in an efficient and effective manner and will achieve full compliance with drug laws and regulations when representing Kura and Kura’s products to Healthcare Providers. 

ESSENTIAL JOB FUNCTIONS:

• Achieve the assigned sales objective for the territory
• Attain the designated goals for calls on appropriate healthcare professionals to communicate balanced, accurate, and complete information on Kura’s FDA approved products
• Develops and implements a territory business plan to meet customer needs and achieve goals
• Navigate through complex external/customer organizational structures including hospitals, IDNs, GPOs and healthcare communities while aligning with cross-functional commercial partners
• Demonstrate completion of administrative requirements including budget management, expense reports management, CRM call reporting and synchronization, etc. within timelines and company guidelines
• Demonstrates a deep understanding of healthcare professionals (HCP) and account needs, effectively utilizing this knowledge to strategically promote and expand the use of assigned products
• Operate the territory within the assigned expense budget and demonstrates fiscal responsibility
• Comply with all federal/state/local laws, regulations and guidelines including but not limited to the PhRMA Code on Interactions with Healthcare Professionals as well as complying with all Kura standards and policies relating to all job activities
• Successful completion and ongoing updates of all aspects of training including but not limited to product knowledge, disease state, market, selling skills and compliance
• Assists in the identification and resolution of issues and opportunities while communicating proactively to marketing and sales management
• Develops and consistently demonstrates an expert understanding of HCP and Account needs to appropriately expand use of assigned product. 

JOB SPECIFICATIONS:

• Undergraduate degree required, ideally in business/marketing/healthcare/life science areas of concentration
• 6+ years of successful pharmaceutical/biotech sales experience with 3+ in the oncology/hematology and/or rare disease markets, preferably with oral therapeutic selling experience
• Management of large territories that includes periodic overnight travel
• Occasionally work evenings and weekends as needed for conferences
• Excellent written and oral communication skills
• Strong computer skills, notably WORD, EXCEL and POWER POINT

The base range for this role is $210,000 to $230,000 per year with a target IC of 60k. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. 

If you are a California resident, please see the attached Privacy Notice CA Privacy Notice